pp-141 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Liver fibrosis/MASH (NASH); solid tumours (in combination with checkpoint inhibitors)
Clinical stage: Phase 2
Modality: Small molecule
Mechanism / Target: Galectin-3 inhibitor — blocks galectin-3-mediated activation of hepatic stellate cells (fibrosis), TGF-β signalling, and tumour immune exclusion
Route / form: Oral tablet (twice daily)
Differentiation: First-in-class galectin-3 inhibitor in Phase 2; dual anti-fibrotic and immunomodulatory potential; oral; target well-validated in preclinical models
Manufacturer #39172
Clinical-stage biotechnology company targeting galectin proteins in fibrosis and oncology. Develops first-in-class galectin-3 inhibitors with dual anti-fibrotic and anti-tumour rationale. Wholly owned oral pipeline advancing in liver disease and cancer.
None